Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance
Authors:
- Panagiotis PapageorgisPanagiotis Papageorgis
- Christiana CharalambousCCChristiana Charalambous
- Andreas I. ConstantinouACAndreas I. Constantinou
- 1 September 2013
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 337 (2) , 167-176
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Binding of estrogen receptor α/β heterodimers to chromatin in MCF-7 cellsJournal of Molecular Endocrinology, 2009
- Estrogen Receptor (ER) β Modulates ERα-Mediated Transcriptional Activation by Altering the Recruitment of c-Fos and c-Jun to Estrogen-Responsive PromotersMolecular Endocrinology, 2006
- Clinical significance of estrogen receptor β in breast cancerCancer Chemotherapy and Pharmacology, 2005
- Differential expression of the estrogen receptor beta (ERβ) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinomaThe Prostate, 2002
- DNA methylation and cancerOncogene, 2002
- Quantitative analysis of estrogen receptor-? mRNA and its variants in human breast cancersInternational Journal of Cancer, 2000
- Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 SitesScience, 1997
- ERβ: Identification and characterization of a novel human estrogen receptorFEBS Letters, 1996
- The Role of Estrogen in Mammary CarcinogenesisaAnnals of the New York Academy of Sciences, 1995
- MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERSAnnual Review of Biochemistry, 1994